Palatin Technologies Inc

Price Chart

Risk-Adjusted Performance

Palatin Technologies Inc (PTN) Price Performance

Palatin Technologies Inc (PTN) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $22.32, up 2.17% from the previous close.

Over the past year, PTN has traded between a low of $4.00 and a high of $28.00. The stock has gained 112.6% over this period. It is currently 20.3% below its 52-week high.

Palatin Technologies Inc has a market capitalization of $38.01M.

About Palatin Technologies Inc

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Compare Palatin Technologies Inc

Side-by-side comparison against top Healthcare peers.